prednisone has been researched along with Malnutrition in 6 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Malnutrition: An imbalanced nutritional status resulting from insufficient intake of nutrients to meet normal physiological requirement.
| Excerpt | Relevance | Reference |
|---|---|---|
| ", we analyzed 262 patients who had been treated with Ruximab-cyclophosphamide, doxorubicin, vincristine, and prednisone for newly diagnosed diffuse large B-cell lymphoma (DLBCL) and for whom data were available regarding pretreatment nutritional status." | 3.80 | Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. ( Cho, JW; Han, B; Kim, S; Kim, SJ; Kim, WS; Park, S; Woo, SY, 2014) |
| " The pharmacokinetic comparability of Prolastin-C to Prolastin was assessed in subjects with AAT deficiency." | 2.75 | Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. ( Brantly, ML; Campos, MA; Chapman, KR; Kueppers, F; Sandhaus, RA; Stocks, JM; Strange, C; Turino, G; Wang-Smith, L, 2010) |
| "Survival for childhood acute lymphoblastic leukemia (ALL) has improved significantly, but these benefits may not be available to many children from low and middle income countries, where reasons for treatment failure may be unique to their environment." | 1.43 | The Impact of Socioeconomic Factors on the Outcome of Childhood Acute Lymphoblastic Leukemia (ALL) Treatment in a Low/Middle Income Country (LMIC). ( Ashraf, MS; Belgaumi, AF; Iftikhar, S; Jabeen, K, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Serrano, OK | 1 |
| Kutzler, HL | 1 |
| Rochon, C | 1 |
| Radojevic, JA | 1 |
| Lawlor, MT | 1 |
| Hammond, JA | 1 |
| Gluck, J | 1 |
| Feingold, AD | 1 |
| Jaiswal, A | 1 |
| Kanemasa, Y | 1 |
| Shimoyama, T | 1 |
| Sasaki, Y | 1 |
| Hishima, T | 1 |
| Omuro, Y | 1 |
| Cockey, G | 1 |
| Shah, SR | 1 |
| Hampton, T | 1 |
| Park, S | 1 |
| Han, B | 1 |
| Cho, JW | 1 |
| Woo, SY | 1 |
| Kim, S | 1 |
| Kim, SJ | 1 |
| Kim, WS | 1 |
| Jabeen, K | 1 |
| Ashraf, MS | 1 |
| Iftikhar, S | 1 |
| Belgaumi, AF | 1 |
| Stocks, JM | 1 |
| Brantly, ML | 1 |
| Wang-Smith, L | 1 |
| Campos, MA | 1 |
| Chapman, KR | 1 |
| Kueppers, F | 1 |
| Sandhaus, RA | 1 |
| Strange, C | 1 |
| Turino, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multi-center, Randomized, Double-blind, Crossover Trial to Evaluate the Pharmacokinetic Comparability of Alpha-1 MP to Prolastin in Subjects With Alpha1-antitrypsin Deficiency.[NCT00295061] | Phase 3 | 24 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary objective of this study was to demonstrate the pharmacokinetic comparability (geometric least square mean ratio of AUC between the Alpha-1 MP vs. Prolastin®, 90% confidence interval falls within 0.80-1.25, FDA Guidance as being bioequivalent between two treatments) of Alpha-1 MP to Prolastin® in subjects with alpha-1-anti-trypsin (AAT) deficiency by comparing AUC from Day 0 to Day 7 of plasma Alpha1-PI measured by the functional activity (potency) assay. AUC from Day 0 to Day 7 was calculated at steady state at the end of the first and second 8-week treatment periods during the 16-week double-blind, crossover phase." (NCT00295061)
Timeframe: Day 0 to Day 7
| Intervention | mg*h/mL (Number) |
|---|---|
| Alpha-1 MP | 155.9 |
| Prolastin | 152.4 |
1 trial available for prednisone and Malnutrition
| Article | Year |
|---|---|
Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study.
Topics: alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; Antineoplastic Combined Chemotherapy Protocols; | 2010 |
5 other studies available for prednisone and Malnutrition
| Article | Year |
|---|---|
Incidental COVID-19 in a heart-kidney transplant recipient with malnutrition and recurrent infections: Implications for the SARS-CoV-2 immune response.
Topics: Antibiotics, Antineoplastic; Bacteremia; BK Virus; Cardiomyopathy, Dilated; Cardiotoxicity; COVID-19 | 2020 |
Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic | 2018 |
Giant Cell Arteritis Presenting with a Tongue Lesion.
Topics: Aged, 80 and over; Biopsy; Deglutition Disorders; Diagnosis, Differential; Female; Gastrostomy; Gian | 2019 |
Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthropometry; Antibodies, Monoclonal, Murine-Derived; A | 2014 |
The Impact of Socioeconomic Factors on the Outcome of Childhood Acute Lymphoblastic Leukemia (ALL) Treatment in a Low/Middle Income Country (LMIC).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2016 |